Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Ironwood Bark from Xylia xylocarpa contains up to 12% tannins and novel compounds like xylocarpol that inhibit inflammatory pathways including COX-2 and NF-κB. The bark's ellagitannins and lupeol provide antimicrobial effects through cell wall disruption and oxidative stress modulation.
Reported Benefits (Provisional)
Origin & History
Ironwood Bark refers to barks from distinct species: Mesua ferrea from South Asia and Olneya tesota from the Southwestern United States/Mexico. Both are traditionally valued for their robust antimicrobial, anti-inflammatory, and wound-healing properties, supporting skin and digestive health.
Research Narrative (Provisional)
Research on Ironwood Bark, particularly Mesua ferrea, highlights its significant antimicrobial, anti-inflammatory, and wound-healing properties, attributed to its rich content of xanthones and phenolic acids. Studies support its traditional applications for skin repair and infection control, with ongoing investigation into the unique compounds of Olneya tesota.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals (General): Tannins, flavonoids, triterpenes, lignans. - Phytochemicals (Mesua ferrea specific): Xanthones, phenolic acids. - Phytochemicals (Olneya tesota specific): Unique polyphenolic compounds, antimicrobial phytochemicals.
Reported Mechanism (Provisional)
Ironwood Bark's bioactive compounds target multiple pathways: xylocarpol scavenges free radicals and downregulates pro-inflammatory cytokines, while lupeol (0.2-0.5% in extracts) modulates oxidative stress for hepatoprotective effects. The bark's ellagitannins and condensed tannins (up to 12% concentration) disrupt microbial cell walls and inhibit COX-2/NF-κB inflammatory signaling. β-sitosterol regulates T-cell proliferation and immune modulation without overstimulation.
Clinical Narrative (Provisional)
Human clinical trials on Ironwood Bark remain limited, with most evidence from animal and in vitro studies. A rodent study showed bark decoction at 200 mg/kg reduced paw edema by approximately 45%, while animal hepatoprotection studies demonstrated reduced liver enzymes (AST/ALT). One preliminary human study in Thailand found 2-week supplementation mildly increased white blood cell counts, though specific increments were not quantified. Large-scale randomized controlled trials are lacking, limiting clinical evidence strength.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.